Analyst says acquisition strengthens Coloplast's core competencies

The acquisition of the Swedish company Atos Medical could lay the foundation for further top line growth and increased revenue for Coloplast, a Sydbank analyst assesses.

Photo: Coloplast / PR

Coloplast's acquisition of Atos Medical could prove to be a solid growth driver within the Danish medtech company's chronic care business, says Senior Analyst at Sydbank Søren Løntoft Hansen.

Atos Medical is right up Coloplast's alley when it comes to its core competencies, and could therefore pave the way for further growth in terms of top line and revenue, he assesses.

Read the whole article

Get 14 days free access.
No credit card required.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

"Real world" patient data documents the long-term effects of ALK vaccines

In the largest study ever of its kind, patient data from the "real world" documents the long-term effects of up to nine years of ALK vaccines. Up until now, it has not been possible to demonstrate these in ordinary clinical studies where the follow-up period is shorter, and the new knowledge could be a turning point in ALK's dialog about prices and subsidies with authorities and payers. 

Further reading

Related articles

Latest news

See all jobs